Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.75 |
| ▸ | HPGD | P15428 | 7/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | CA1 | P00915 | 2/20 | 0.75 |
| ▸ | CA2 | P00918 | 2/20 | 0.75 |
| ▸ | CA12 | O43570 | 1/20 | 0.75 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.75 |
| ▸ | CA4 | P22748 | 1/20 | 0.75 |
| ▸ | CA6 | P23280 | 1/20 | 0.75 |
| ▸ | CA7 | P43166 | 1/20 | 0.75 |
| ▸ | CA9 | Q16790 | 1/20 | 0.75 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4295686 | 0.91 | KDM4E (0.82) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL31490109 | 0.91 | KDM4E (0.82) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL28820609 | 0.89 | KDM4E (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL8176134 | 0.89 | KDM4E (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL9228055 | 0.88 | KDM4E (0.75) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL6725453 | 0.88 | KDM4E (0.75) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL30940555 | 0.88 | KDM4E (0.75) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL11514985 | 0.88 | KDM4E (0.75) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL3409946 | 0.87 | ALDH1A1 (0.82) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| Phthalic Acid SCHEMBL28283849 | 0.87 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5015648-A | 7-(((1,1*-biphenyl)4-yl)-3-hydroxy-2-(1-piperidinyl) cyclopenty l)-4-hepteoic acid or cyclodextran derivative | GLAXO GROUP LIMITED (GB) | 1991-05-14 | — | — | US | disclosed |
| EP-0335627-A2 | Use of a thromboxane antagonist in cyclosporin A-induced nephrotoxicity | GLAXO GROUP LIMITED (GB) | 1989-10-04 | — | — | EP | disclosed |